Sanofi (SNY) and Earendil Labs have signed a licensing deal for two bispecific antibodies that target autoimmune and inflammatory bowel diseases, Earendil Labs said in a statement Thursday.
Sanofi will gain exclusive global rights to drug candidates HXN-1002 and HXN-1003 once the deal closes, according to the statement.
Earendil will receive an upfront payment of $125 million from Sanofi, it added.
Earendil could earn up to $1.72 billion in development and commercial milestones, including a $50 million payment expected soon after closing, Earendil Labs said.
Earendil is also eligible for tiered sales royalties that start in the high single digits and rise to the low double digits, the statement added.
Sanofi's shares were up about 1.6% in recent trading.
Price: 51.35, Change: +0.79, Percent Change: +1.56
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.